1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bone Biologics Corporation

Bone Biologics Corporation

BBLGW
Bone Biologics CorporationUS flagNASDAQ Capital Market
4.00
USD
-0.54
- -
765,516.00Market Cap

Total Valuation

Bone Biologics Corporation carries a market capitalization of 765,516.00, placing it among publicly traded companies globally. Its enterprise value stands at 22.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap765,516.00
Enterprise Value22.22M

Share Statistics

Bone Biologics Corporation currently has 1.81M shares outstanding.

Shares Outstanding1.81M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

PE RatioN/A
PS RatioN/A
PB Ratio6.69
P/TBV Ratio6.69
P/FCF RatioN/A
P/OCF RatioN/A

Financial Position

Bone Biologics Corporation maintains a current ratio of 8.67, meaning it holds 8.7x the short-term assets needed to cover near-term liabilities.

Current Ratio8.67
Quick Ratio7.89
Debt / EquityN/A
Debt / EBITDAN/A
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-54.96
Return on Assets (ROA)-50.55
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Bone Biologics Corporation's stock has declined approximately -62.92864% over the past 52 weeks. The 50-day moving average sits at 9.57, while the 200-day moving average is 17.29.

Beta (5Y)N/A
52-Week Price Change-62.92864%
50-Day Moving Average9.57
200-Day Moving Average17.29
Average Volume (20 Days)N/A

Income Statement

EBITDA reached -3.06M, while operating income came in at -3.06M.

RevenueN/A
Gross ProfitN/A
Operating Income-3.06M
Pretax Income-2.89M
Net Income-2.89M
EBITDA-3.06M
EBIT-3.06M
Earnings Per Share (EPS)N/A

Balance Sheet

Total book value stands at 3.92M, with working capital of 3.92M providing operational flexibility.

Cash & Cash Equivalents4.03M
Total DebtN/A
Net Debt-4.03M
Equity (Book Value)3.92M
Book Value Per Share2.17
Working Capital3.92M

Cash Flow

Bone Biologics Corporation produced -2.63M in operating cash flow over the past twelve months.

Operating Cash Flow-2.63M
Capital ExpendituresN/A
Free Cash Flow-2.63M
FCF Per ShareN/A

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-0.08
FCF YieldN/A

Stock Splits

Bone Biologics Corporation's most recent stock split took place on June 10, 2025 with a 6:1 split ratio.

Last Split Date6/10/2025
Split Ratio6:1

Scores

Bone Biologics Corporation posts an Altman Z-Score of 1.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.25